Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In this issue

In this issue Lentiviral vectors for CNS disorders: a review There has been a continuing evolution of the design of lentiviral vectors, with the trend being to remove as much viral sequence as possible from the transfer genome. This review by Azzouz et al. focuses mainly on the general features of the vector system derived from the non‐primate lentivirus, equine infectious anemia virus (EIAV). Indeed, EIAV lentiviral vectors are well characterised and provide powerful tools for gene therapy approaches to the nervous system since they are extremely efficient at transducing neuronal cell‐types, both in vitro and in vivo . Numerous in vivo studies have now been undertaken with these vectors and correction of disease models has been obtained. Remarkably, these vectors have been refined to a very high level and can be produced safely for the clinic. The prospects for clinical application of this lentiviral vector system for the treatment of Parkinson's disease and motor neuron diseases are also outlined. Safe two‐plasmid production system for clinical lentivirus vector Lu et al. have designed a unique two‐plasmid production system for the first lentiviral vector to be evaluated in humans, VRX496. VRX496 is an optimized VSV‐G pseudotyped vector derived from HIV‐1 that expresses http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Gene Medicine Wiley

In this issue

Journal of Gene Medicine , Volume 6 (9) – Sep 1, 2004

Loading next page...
 
/lp/wiley/in-this-issue-tGLW6wBG3o

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Copyright © 2004 John Wiley & Sons, Ltd.
ISSN
1099-498X
eISSN
1521-2254
DOI
10.1002/jgm.667
Publisher site
See Article on Publisher Site

Abstract

Lentiviral vectors for CNS disorders: a review There has been a continuing evolution of the design of lentiviral vectors, with the trend being to remove as much viral sequence as possible from the transfer genome. This review by Azzouz et al. focuses mainly on the general features of the vector system derived from the non‐primate lentivirus, equine infectious anemia virus (EIAV). Indeed, EIAV lentiviral vectors are well characterised and provide powerful tools for gene therapy approaches to the nervous system since they are extremely efficient at transducing neuronal cell‐types, both in vitro and in vivo . Numerous in vivo studies have now been undertaken with these vectors and correction of disease models has been obtained. Remarkably, these vectors have been refined to a very high level and can be produced safely for the clinic. The prospects for clinical application of this lentiviral vector system for the treatment of Parkinson's disease and motor neuron diseases are also outlined. Safe two‐plasmid production system for clinical lentivirus vector Lu et al. have designed a unique two‐plasmid production system for the first lentiviral vector to be evaluated in humans, VRX496. VRX496 is an optimized VSV‐G pseudotyped vector derived from HIV‐1 that expresses

Journal

Journal of Gene MedicineWiley

Published: Sep 1, 2004

There are no references for this article.